Beginning Cash: The amount of cash reported by the company on its previous statement.
Janux Therapeutics, Inc. (JANX) had Beginning Cash of $431.42M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-23.51M |
|
-- |
|
-- |
|
$34.90M |
|
$-34.90M |
|
$11.39M |
|
$-23.51M |
|
$-23.51M |
|
$-23.51M |
|
$-23.51M |
|
$-23.51M |
|
$-23.51M |
|
$-34.90M |
|
$-38.60M |
|
61.79M |
|
61.79M |
|
$-0.38 |
|
$-0.38 |
|
| Balance Sheet Financials | |
$1.02B |
|
$4.95M |
|
$27.43M |
|
$1.05B |
|
$17.50M |
|
-- |
|
$20.80M |
|
$38.30M |
|
$1.01B |
|
$1.01B |
|
$1.01B |
|
59.17M |
|
| Cash Flow Statement Financials | |
$-17.02M |
|
$-340.39M |
|
$0.55M |
|
|
Beginning Cash |
$431.42M |
$74.56M |
|
$-356.86M |
|
$10.70M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
58.47 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-17.39M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-2.32% |
|
-2.32% |
|
-2.24% |
|
-2.32% |
|
$17.11 |
|
$-0.28 |
|
$-0.28 |
|